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The utilization of health-related quality of life (HRQoL) questionnaires in routine clinical practice is hampered
by several factors, including their length and thus the time needed to complete and score them. For this reason,
growing efforts are devoted both to create short questionnaires and to shorten existing ones. The Skindex-17 is
a dermatological HRQoL instrument that was derived from the Skindex-29 using Rasch analysis. It consists of
17 items instead of 29, and answers are given on a three-point scale instead of a five-point scale. The aim of this
study was to compare information obtained by the Skindex-29 and the Skindex-17 in a large sample of
dermatological outpatients. We compared the Skindex-29 with the Skindex-17 scores in 2,487 patients with
several dermatological conditions, using intraclass correlation coefficients. The overall correlation was 0.957 for
the symptoms scale and 0.940 for the psychosocial scale. The values were very similar for all diseases. The
concordance between the levels of severity of the Skindex subscales in the two instruments was also very high.
In conclusion, the Skindex-17 provided very similar information compared with the Skindex-29, with the
advantage of being shorter and including some important psychometric properties.
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INTRODUCTION
The measurement of health-related quality of life (HRQoL)
in dermatological patients is now recognized as an
important step in the knowledge of the burden that skin
disease may pose on patients. HRQoL has become
an essential outcome parameter in randomized controlled
clinical trials, clinical research, clinical practice, and health-
care management.
Many HRQoL instruments are available in dermatology;
however, their psychometric characteristics have not always
been properly evaluated (Both et al., 2007), and often there
are no indications for the interpretation of the results. The
Skindex-29 (Chren et al., 1997a, 1997b) is recognized as one
of the best HRQoL dermatological instruments (de Korte
et al., 2002). Its properties have been thoroughly evaluated,
and different studies have been conducted for the interpreta-
tion of its scores (Nijsten et al., 2009; Prinsen et al., 2010,
2011). A recent review of HRQoL measurement in dermatol-
ogy recommended the combination of the Skindex-29 and
the 36-Item Short Form Health Survey (SF-36) as the
instruments of choice in dermatology (Both et al., 2007).
However, although in clinical research the administration
of questionnaires is a feasible task, the utilization of HRQoL
in clinical practice is hampered by several factors, such as the
time necessary to complete the questionnaire, its length, and
the need for accurate data entry and data management to
obtain a final score. For this reason, the shorter a ques-
tionnaire is, the easier it will be for the dermatologist to
administer it during routine daily practice.
A shorter questionnaire was derived from the Skindex-29
using Rasch analysis: the Skindex-17 (Nijsten et al., 2006).
It is composed of 17 items, and answers are given on a
three-point scale instead of a five-point scale. The aim of
this study was to compare information obtained by the
Skindex-29 and the Skindex-17 in a large sample of
dermatological outpatients, to evaluate similarities and
discrepancies between the scores obtained from the two
versions of the Skindex, and to determine whether the use of
the shorter form of the questionnaire might cause a loss of
information.
RESULTS
Questionnaires were given to 3,999 patients, and 2,732
agreed to participate (response rate 68%).
Sixty-one physicians participated in the study. Data were
complete for 2,487 patients. Of them, 58.6% were women.
The mean (SD) age for men and women was 46.5 (18.3) and
45.0 (17.8), respectively.
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Table 1 shows the mean values of the Skindex-29 and the
Skindex-17 scores, and their correlation in different derma-
tological conditions. The overall intraclass correlation coeffi-
cient was 0.957 for the symptoms scale and 0.940 for the
psychosocial scale. The values were very similar for all
diseases.
The mean values of the Skindex-29 and of the Skindex-17
in different levels of different variables are reported in
Table 2. With the only exception of gender in the symptoms
scale (Skindex-29 mean value was higher in women than in
men, whereas there was no difference for the Skindex-17)
and marital status in the psychosocial scale, there was
concordance between Skindex-29 and Skindex-17 in the
differences for all the variables.
Higher scores of the symptoms scale of both Skindex were
associated with lower education and with higher disease
severity, both from the point of view of the physician and of
the patient. The psychosocial scores were higher in women,
in younger patients, and in patients with higher disease
severity, for both instruments.
Table 1. Mean values of the Sk-29 and of the Sk-17
scores and their ICC in different dermatological
conditions
Symptoms Psychosocial
n Sk-29 Sk-17 ICC Sk-29 Sk-17 ICC
Acne 193 33.2 37.3 0.939 32.1 33.6 0.927
Alopecia androgenetic 77 13.0 15.5 0.950 16.3 16.4 0.901
Alopecia areata 52 9.9 9.8 0.948 22.0 23.4 0.929
Bacterial infections 53 40.2 44.6 0.910 26.0 26.0 0.907
Balanitis 25 33.6 37.2 0.889 24.0 27.2 0.951
Benign skin neoplasias 175 13.9 15.7 0.930 10.0 8.2 0.907
Dermatitis 249 45.1 50.2 0.942 25.9 26.6 0.937
Hair loss 27 17.8 21.1 0.968 22.3 21.2 0.941
Lichen planus 32 34.2 38.4 0.942 20.3 16.8 0.914
Mycoses 116 28.1 31.8 0.954 17.4 17.0 0.925
Nail conditions 38 17.4 20.0 0.964 17.0 15.0 0.862
Nevi 306 10.3 12.3 0.925 8.7 6.7 0.911
Non-melanoma skin
cancers
79 18.2 19.6 0.930 12.8 9.2 0.890
Pemphigus/bullous
diseases
17 44.2 46.0 0.968 38.3 37.0 0.983
Pityriasis rosea 29 27.6 31.1 0.882 21.0 19.6 0.920
Pruritus 54 49.2 53.7 0.903 29.4 24.8 0.953
Psoriasis 220 47.9 54.2 0.946 32.5 33.0 0.941
Rosacea 60 33.3 33.2 0.951 26.2 26.1 0.953
Scabies and other
ectoparasitic infections
34 51.5 57.0 0.942 40.7 40.8 0.935




49 35.2 40.0 0.954 28.5 29.2 0.953
Seborrheic dermatitis 85 33.5 36.3 0.942 19.1 20.2 0.906
Urticaria 29 44.8 44.8 0.908 27.5 28.4 0.921
Viral infections 68 19.9 21.1 0.946 18.0 16.9 0.939
Vitiligo and other
pigmentation disorders
54 12.0 11.3 0.916 19.5 20.3 0.921
Other dermatoses 60 39.1 41.3 0.948 29.0 30.3 0.920
Missing and other
diagnoses
287 28.2 29.6 0.956 21.2 20.9 0.929
Overall 2,487 28.9 31.9 0.957 21.6 21.1 0.940
Abbreviations: ICC, intraclass correlation coefficient; Sk-17, Skindex-17;
Sk-29, Skindex-29.
Table 2. Mean values of the Sk-29 and of the Sk-17
scale scores, and their ICC in different levels of
variables of interest
Symptoms Psychosocial
Variable Level N1 Sk-29 Sk-17 ICC Sk-29 Sk-17 ICC
Overall 2,487 28.9 31.9 0.957 21.7 21.1 0.940
Gender Male 1,022 27.2 31.0 0.952 19.5 19.4 0.941
Female 1,449 30.1** 32.5 0.960 23.2** 22.4** 0.939
Age (years) 18–29 630 27.6 30.8 0.957 23.5 23.5 0.942
30–39 510 28.2 31.4 0.963 21.9 22.4 0.932
40–49 412 29.9 33.5 0.960 22.1 21.3 0.937
50–64 467 31.0 34.0 0.954 21.3 20.8 0.943
65+ 446 28.5 30.4 0.948 18.4** 15.5** 0.948
Education None 33 34.3 35.2 0.941 26.1 22.8 0.892
Primary 217 35.4 37.4 0.945 23.9 19.9 0.959
Middle 485 31.5 33.9 0.956 22.7 21.9 0.948
High 1,063 27.9 31.3 0.960 21.1 20.6 0.940
University 602 26.1** 29.3** 0.955 20.6 21.4 0.930
Marital
status
Single 1,045 27.8 30.9 0.960 22.2 22.5 0.937
Married/
partner
1,092 29.8 32.6 0.954 20.8 19.4 0.940
Separated/
divorced
145 29.8 33.3 0.964 24.3 23.9 0.950
Widow/er 126 32.6 35.0 0.947 22.8 20.7* 0.952
PhGA Very mild 242 16.4 17.7 0.956 13.4 11.5 0.912
Mild 937 25.4 27.9 0.950 18.2 17.3 0.932
Moderate 889 33.1 36.6 0.956 25.0 24.9 0.945
Severe 177 42.0 47.4 0.960 33.5 35.7 0.933
Very severe 32 50.0** 54.2** 0.966 42.1** 43.2** 0.926
PtGA Very mild 442 14.4 16.5 0.942 9.5 8.4 0.919
Mild 761 24.2 27.0 0.944 17.1 16.2 0.921
Moderate 702 36.4 39.8 0.944 26.5 27.1 0.918
Severe 218 48.0 52.5 0.958 40.8 42.8 0.920
Very severe 77 58.3** 61.4** 0.962 48.1** 49.1** 0.944
Abbreviations: ANOVA, analysis of variance; ICC, intraclass correlation
coefficient; Sk-17, Skindex-17; Sk-29, Skindex-29; PhGA, physician
global assessment; PtGA, patient global assessment.
*Po0.05, **Po0.01 from the t-test and the ANOVA for the comparison
among the different levels of each variable.
1Totals vary because of missing figures.
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The comparison between the categorization of the
Skindex-29 and the Skindex-17 for the different subscales is
reported in Table 3. The concordance was very high, with a
P-value lower than 0.001 for each of the comparisons. In the
symptoms scale, 99.1% of patients who were included in
the classes ‘‘very mild’’ to ‘‘moderate’’ in the Skindex-29
were grouped in the ‘‘not severe’’ category of the Skindex-17,
and 96.5% of patients considered as ‘‘very severe’’ in the
Skindex-29 categorization were categorized in the ‘‘severe’’
class of the Skindex-17. However, there were also 411
patients with a severe or very severe impairment in HRQoL
according to the Skindex-29, who were classified as having a
‘‘not severe’’ impairment by the Skindex-17.
The comparison of the psychosocial scale of the Skindex-
17 with the emotions subscale of the Skindex-29 showed a
high concordance for the ‘‘severe’’ class of both instruments
(84.0% of patients), and for the ‘‘very mild’’ class of the
Skindex-29 and the ‘‘mild’’ category of the Skindex-17
(99.7%). The concordance of the psychosocial scale of the
Skindex-17 was higher with the functioning scale of the
Skindex-29 than with the emotions scale. In fact, 92.9% of
patients were classified as ‘‘severe’’ by both instruments and
100.0% of ‘‘very mild’’ and 83.2% of ‘‘mild’’ were in the
‘‘mild’’ class of the Skindex-17.
Table 4 summarizes the results of the differential item
functioning (DIF) analysis. Although several items of the
Skindex-17 showed a significant DIF, it is notable that in all
cases, the corresponding Skindex-29 items also had a
significant DIF. In addition, item 29 of the Skindex-29 (i.e.,
sex life) had a significant DIF, whereas the corresponding
item in the Skindex-17 did not.
DISCUSSION
In the present study, we observed a very high concordance
between the Skindex-29 and the Skindex-17 scores in a large
group of patients with different dermatological conditions.
The Skindex-29 is a well-designed, validated, and exten-
sively used dermatological HRQoL questionnaire, and it is
already a refinement of a 61-item version (Chren et al., 1996)
obtained using classical test theory to retain or discard items.
The concepts and the assumptions of classical test theory have
been the foundation for measurement theory for over 80
years. Afterward, methods based on item response theory,
such as the Rasch model (Rasch, 1960–1980; Streiner and
Norman, 1989; Tennant et al., 2004), have been suggested
to be used in psychometrics. Compared with classical test
theory, these approaches have the ability to solve some
problems such as response order (i.e., logical ordering of the
response categories), additivity, which requires unidimension-
ality of the measurement, and DIF (i.e., assessing the effect
of external factors on item response) (McHorney, 1997;
Tesio, 2003; Tennant et al., 2004). The Skindex-17 is a
Table 3. Comparison between the categorization of the Skindex-29 and the Skindex-17 for the different subscales
Skindex-29 symptoms
Skindex-17 symptoms Very mild (0–3.9) Mild (4–10.9) Moderate (11–25.9) Severe (26–49.9) Very severe (50+)
Not severe (0–49.9) 566 (100%) 241 (100%) 444 (99.1%) 391 (66.6%) 20 (3.5%)
Severe (50+) 0 (0.0%) 0 (0.0%) 4 (0.9%) 196 (33.4%) 554 (96.5%)
Skindex-29 emotions
Skindex-17 psychosocial
Very mild (0–5.9) Mild (6–24.9) Moderate (25–49.9) Severe (50+)
Mild (0–20.82) 398 (99.7%) 749 (89.4%) 238 (32.7%) 5 (1.4%)
Moderate (20.83–37.5) 1 (0.3%) 88 (10.5%) 316 (43.5%) 54 (14.6%)
Severe (37.51+) 0 (0.0%) 1 (0.1%) 173 (23.8%) 310 (84.0%)
Skindex-29 functioning
Skindex-17 psychosocial
Very mild (0–3.9) Mild (4–10.9) Moderate (11–32.9) Severe (33+)
Mild (0–20.82) 844 (100.0%) 431 (83.2%) 115 (20.0%) 0 (0.0%)
Moderate (20.83–37.5) 0 (0.0%) 84 (16.2%) 347 (60.2%) 28 (7.1%)
Severe (37.51+) 0 (0.0%) 3 (0.6%) 114 (19.8%) 367 (92.9%)
The psychosocial scale of the Skindex-17 was compared with both the emotions and the functioning scale of the Skindex-29, as it was derived from both of
them. P-values from w2-test were always lower than 0.001.
The cutoffs of the Skindex-17 scores (here on a 0–100 scale) correspond to 5 for the symptoms, and 5 and 9 for the psychosocial scale, as originally published
(Nijsten et al., 2006). The cutoffs of the Skindex-29 are those originally published in Nijsten et al. (2009).
The range of the categories of both instruments are reported in parenthesis.
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Rasch-reduced version of the Skindex-29, and thus, it was
derived with the aim of having all those properties.
Moreover, the Skindex-17 has the practical advantage
of being shorter than the Skindex-29. Not only does it
have fewer items but also the possible answers are on a
three-point scale instead of a five-point scale, making it
quicker to fill for the patient. As underlined by the authors
(Nijsten et al., 2006), collapsing or reducing response
categories does not necessarily decrease the precision of
an HRQoL instrument (Piccinelli et al., 1993; de Jong
et al., 1997).
The choice of an HRQoL instrument to be used in clinical
practice is mainly based on its psychometric properties, but
its length is not a trivial aspect. In the busy daily-routine
clinical practice, the dermatologist often has very limited
time to wait for the patient to fill in the questionnaire, and
patients prefer short and clear questionnaires (Mehanna and
Morton, 2006).
The very high correlation between the Skindex-29 and
Skindex-17 observed in this study suggested that the Skindex-
17 might be used instead of the older and longer version
without losing any significant information. This was true for
all the observed diagnostic categories and for the different
subscales of the instrument.
In addition, DIF analysis for the different diagnoses
confirmed that the Skindex-17 items behaved at least as
well as the corresponding ones in the Skindex-29, and among
the common items, there was actually one less item with a
significant DIF.
However, the Skindex-17 is still a young instrument,
whose psychometric properties and clinical value need to be
tested in other populations. On the other hand, the Skindex-
29 is an instrument used worldwide, with several interna-
tional versions, and for which the psychometric properties
have been verified countless times. Moreover, in the Skindex-
17, the emotions and functioning scales are combined,
which simplifies the instruments, but results in a loss of
information, as, of the two scores yielded by the Skindex-29,
only one is available for the Skindex-17. In addition, the
psychosocial scale is mostly composed of functioning items,
and in fact it correlates more with the functioning scale of the
Skindex-29 than with the emotions scale of the original
instrument. Furthermore, specific pieces of information
available in a single-item analysis (Sampogna et al., 2004,
2008) may be lost. For example, if one is interested in
knowing how often a given condition ‘‘burns or stings,’’ this
information would be available from the Skindex-29, but not
from the Skindex-17.
On the basis of our results, the administration of the
Skindex-17 instead of the Skindex-29 seems to provide very
similar information while requiring less time and effort for
completion, and data entry, and thus for the production of the
scale scores. This is particularly desirable when limited time
and resources are available, which is usually the case in
clinical practice.
However, further studies are needed to investigate
whether the Skindex-17 can effectively replace the Skindex-
29 while providing comparable information. In particular,
more information on patients from different socio-cultural
areas and environments would be desirable. In addition, both
the validation study of the Skindex-17 and this study have
been performed on outpatients, so that other studies
Table 4. P-values from the differential item





1. My skin hurts 1 o0.001 o0.001
2. My skin condition affects how well I
sleep
0.017
3. I worry that my skin condition may be
serious
o0.001
4. My skin condition makes it hard to
work or do hobbies
2 0.197 0.079
5. My skin condition affects my social life 3 0.056 0.170
6. My skin condition makes me feel
depressed
4 0.008 0.014
7. My skin condition burns or stings o0.001
8. I tend to stay at home because of my
skin condition
5 0.196 0.058
9. I worry about getting scars from my
skin condition
o0.001
10. My skin itches 6 o0.001 o0.001
11. My skin condition affects how close I
can be with those I love
7 0.659 0.616
12. I am ashamed of my skin condition o0.001
13. I worry that my skin condition may get
worse
o0.001
14. I tend to do things by myself because of
my skin condition
8 0.724 0.254
15. I am angry about my skin condition 0.011
16. Water bothers my skin condition
(bathing, washing hands)
9 0.158 0.140
17. My skin condition makes showing
affection difficult
10 0.478 0.719
19. My skin is irritated 11 o0.001 o0.001
20. My skin condition affects my
interactions with others
0.206
21. I am embarrassed by my skin condition 12 o0.001 o0.001
22. My skin condition is a problem for the
people I love
0.023
23. I am frustrated by my skin condition 13 o0.001 0.005
24. My skin is sensitive 0.235
25. My skin condition affects my desire to
be with people
14 0.073 0.363
26. I am humiliated by my skin condition 15 0.216 0.558
27. My skin condition bleeds 16 o0.001 o0.001
28. I am annoyed by my skin condition o0.001
29. My skin condition interferes with my
sex life
17 0.010 0.123
30. My skin condition makes me tired 0.096
Bold P-values indicate significant differential item functioning.
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including inpatients or patients seen at day hospital clinics
may be useful.
MATERIALS AND METHODS
Dermatological patients were recruited consecutively during the
normal outpatient clinic activities of the IDI-IRCCS, a large reference
hospital in Rome, Italy, during a survey about HRQoL conducted in
the month of March 2010.
HRQoL and psychological questionnaires were provided to all
patients asking for a dermatological visit. Questionnaires were
completed during the waiting time, and they were returned during
the visit to the dermatologist, who reported on the same
questionnaire the diagnosis and his/her evaluation of the clinical
severity. The questionnaires also included data on patients, such as
sex, age, and educational level. Inclusion criteria were as follows:
age 418 years, ability to understand and read Italian, and signed
written informed consent. The study was approved by the Institu-
tional ethical committee and it was conducted according to the
Declaration of Helsinki Principles.
HRQoL data were collected using the Italian version of the
Skindex-29 (Abeni et al., 2001, 2002). The Skindex-29 is a
dermatological instrument that consists of 29 items, with possible
answers on a five-point scale, from ‘‘never’’ to ‘‘all the time.’’ It
constitutes three subscales, measuring symptoms, emotions, and
functioning.
The Skindex-17 questionnaire (Nijsten et al., 2006) constitutes two
subscales, symptoms and psychosocial, and answers are given on a
three-point scale (‘‘never,’’ ‘‘rarely/sometimes,’’ and ‘‘often/always’’).
In this study, as it is really impractical to administer in the same
session two questionnaires with the same questions, we used the
methodology of other comparative studies of related instruments
(Wee et al., 2008) and we derived the Skindex-17 scores for each
question from the answers to the corresponding items of the Skindex-
29. For this aim, we selected the 17 items of the Skindex-17 out of
the 29 of the Skindex-29, and transformed the five-point answers of
the Skindex-29 into the three-point answers of the Skindex-17. As
the Skindex-17 has two subscales and the Skindex-29 has three sub-
scales, for the purposes of this analysis, the emotions and functioning
scales of Skindex-29 were combined into a ‘‘psychosocial’’ scale
resulting from the mean value of the two subscales. All scale scores,
for both the Skindex-29 and the Skindex-17, were trans-
formed to a linear scale of 100, to allow direct comparability of
scores between the two instruments.
We compared the Skindex-29 with the Skindex-17 on the
summary measures using intraclass correlation coefficients that
were obtained by the R free statistical software, Nonlinear Mixed
Effects Models package (www.r-project.org). The intraclass correla-
tion coefficient is equivalent to the Kappa statistic for continuous
values. It has the advantage over the Pearson’s or Spearman’s
correlation coefficient in that it is a true measure of agreement,
combining information on both the correlation and the systematic
differences between the readings (Deyo et al., 1991).
The mean values of the Skindex-29 and of the Skindex-17 were
compared according to gender, age, education, marital status,
physician global assessment, and patient global assessment, using
the t-test or the ANOVA. In addition, the levels of severity of the
Skindex subscales in the two instruments were compared, according
to the cutoffs described in previous reports (Nijsten et al., 2006,
2009), using the w2-test. For the Skindex-17 categories, the ranges
were calculated reporting to a scale 0–100, the cutoffs originally
reported by Nijsten et al. (2006). For example, the cutoff 5 in the
psychosocial scale of the Skindex-17, which has 12 items, becomes
20.82, because the maximum score for 12 items is 24 (the possible
answers being 0, 1, 2), and is derived using the simple formula
5:24¼  :100.
To verify that responses to individual items were affected by
diagnosis in a comparable way in the two instruments, we performed
a DIF analysis (Angoff, 1993) on random subsamples (n¼ 230) of our
study population according to the procedures described in Nijsten
et al. (2006). DIF analysis verifies whether a given construct has a
similar meaning across different subgroups of patients. In this study,
DIF according to skin condition was considered the most likely to
impact differentially on the meaning of the construct of quality of
life. If there is no significant DIF, then the measures for persons in
different groups can legitimately be compared, as they may be
accepted as measuring the same variable. The subsamples for the
DIF analysis were a proportional stratified random selection of
patients with acne, psoriasis, seborrheic dermatitis, alopecia areata,
vitiligo, and mycoses. The interactive computer software program
RUMM2030 (Andrich et al., 2008) was used to perform the DIF
analysis.
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